05:16 AM EDT, 08/21/2026 (MT Newswires) -- Annexin Pharmaceuticals (ANNX.ST) expanded the study of its drug candidate vanexin to include patients with retinal vein occlusion who have received the current standard-of-care treatment. The Nexus study will include patients who have received one injection of an anti-vascular endothelial growth factor, or anti-VEGF, drug, allowing the company to evaluate the safety and tolerability of vanexin when administered shortly following the standard treatment. The company said the expansion is a preparatory step toward including anti-VEGF treatment in a planned phase 2b study involving patients with macular edema.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.